Sign In
Buy ADMA
$8.69
+0.120 (+1.40%)
At Close: Jun 23, 2026
RAMSEY, N.J. and BOCA RATON, Fla., Feb. 24, 2020 (GLOBE NEWSWIRE) -- ADMA Biologics, Inc. (Nasdaq: ADMA) (“ADMA”), an end-to-end commercial biopharmaceutical company dedicated to manufacturing,
ADMA Biologics Receives BioNJ 2020 Innovator Award for ASCENIV™
04:20pm, Tuesday, 11'th Feb 2020
RAMSEY, N.J. and BOCA RATON, Fla., Feb. 11, 2020 (GLOBE NEWSWIRE) -- ADMA Biologics, Inc. (Nasdaq: ADMA), an end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing and
Why ADMA Biologics Is Tumbling 13.5% Today
12:39pm, Friday, 07'th Feb 2020
The company's secondary stock offering was priced below its prior-day closing price.
ADMA Biologics Announces Pricing of Upsized $82.3 Million Public Offering of Common Stock
08:40pm, Thursday, 06'th Feb 2020
RAMSEY, N.J. and BOCA RATON, Fla., Feb. 06, 2020 (GLOBE NEWSWIRE) -- ADMA Biologics, Inc. (Nasdaq: ADMA) (“ADMA” or the “Company”) an end-to-end commercial biopharmaceutical company dedicate
ADMA Biologics Announces Proposed $75 Million Public Offering of Common Stock
04:06pm, Thursday, 06'th Feb 2020
RAMSEY, N.J. and BOCA RATON, Fla., Feb. 06, 2020 (GLOBE NEWSWIRE) -- ADMA Biologics, Inc. (Nasdaq: ADMA) (“ADMA” or the “Company”) an end-to-end commercial biopharmaceutical company dedicate
ADMA Biologics: An Undervalued Pick For 2020
12:17pm, Thursday, 16'th Jan 2020
ADMA Biologics: An Undervalued Pick For 2020
ADMA Biologics: Feeling Very Bullish After Preliminary Q4 2019 Results
10:34am, Tuesday, 14'th Jan 2020
ADMA Biologics: Feeling Very Bullish After Preliminary Q4 2019 Results
Why ADMA Biologics Stock Is Soaring Today
12:00pm, Thursday, 09'th Jan 2020
ADMA's sneak peek at its Q4 results and an encouraging 2020 strategic update are exciting investors.
ADMA Biologics Announces Preliminary Fourth Quarter and Full Year 2019 Revenues and Provides 2020 Strategic Outlook
07:00am, Thursday, 09'th Jan 2020
Achieved Fourth Quarter 2019 Preliminary Unaudited Total Revenues of $11.9 Million, a 193% Increase Over Fourth Quarter 2018
ADMA Biologics Enters Into a Manufacturing and Supply Agreement to Produce and Sell Plasma-Derived Intermediate Fractions
07:00am, Tuesday, 07'th Jan 2020
Agreement is Expected to Add $5-10 Million in Annual Revenues for 2020 and 2021, and $10-20 Million Per Year for 2022 Through 2024
ADMA Biologics Added to NASDAQ Biotechnology Index
07:08am, Tuesday, 17'th Dec 2019
RAMSEY, N.J. and BOCA RATON, Fla., Dec. 17, 2019 (GLOBE NEWSWIRE) -- ADMA Biologics, Inc. (NASDAQ: ADMA) (“ADMA” or the “Company”), a commercial biopharmaceutical company dedicated to manufa
ADMA Biologics Announces Acceptance to the Plasma Protein Therapeutics Association
07:08am, Monday, 04'th Nov 2019
Adam Grossman, President & CEO, to Join PPTA North America Board of Directors Adam Grossman, President & CEO, to Join PPTA North America Board of Directors
ADMA Biologics Adds ASCENIV's First Sale To A Strong List Of 2019 Accomplishments
05:08pm, Thursday, 24'th Oct 2019
ADMA Biologics recently publicized their first commercial sale of their IVIG product, ASCENIV. Now, the company has three commercial products and multiple sources of revenue.
ADMA Biologics Named Company of the Year by BioFlorida
07:48am, Tuesday, 22'nd Oct 2019
RAMSEY, N.J. and BOCA RATON, Fla., Oct. 22, 2019 (GLOBE NEWSWIRE) -- ADMA Biologics, Inc. (NASDAQ: ADMA) (“ADMA” or the “Company”), a commercial biopharmaceutical company dedicated to manufa
ADMA Biologics Announces First Commercial Sales of ASCENIV™
07:48am, Monday, 21'st Oct 2019
RAMSEY, N.J. and BOCA RATON, Fla., Oct. 21, 2019 (GLOBE NEWSWIRE) -- ADMA Biologics, Inc. (NASDAQ: ADMA) (“ADMA” or the “Company”), a commercial biopharmaceutical company dedicated to manufa
